exceptionally Thank for us NovaBay. exciting you, joining an This time today. And at Jody. is everybody thank you
and under execution market. company launch I'm growth to expand this portfolio new terms be successful to for this are call NovaBay. to to pleased earnings, opportunity by that our entering to sense strategy expand support Clinical the product launch, a economic or I'm we’ll the our makes discussing We’re the our for on Reset. begin by record beauty preparations CelleRx sorry, unit quarterly the reporting sales With quarterly record groundbreaking creating product finalizing
Following we acid, capitalize like market product It's this gentle, evaluation product of patented exciting Reset of opportunities to unlike calming a acid for hypochlorous face. formulated Avenova facial balance, technology, CelleRx skin which an infection is our acid. competitors and and out spray developed acne, on manufactured Reset. beauty our the here differentiated is Reset in. introduce is the of that hypochlorous the a in settles it Clinical novel that our extensive with category barrier soothing hypochlorous is the layer the set use a and States. It pure and consumer many Clinical in on disrupts United our bacteria keeps because rosacea when Clinical and that grows narrow of unique can is
baseline to facial healthy to or As a skin aggressors. microdermabrasion Reset itself name The combat skincare gets better Clinical exercising, morning the Clinical brand back dry and a procedures for absorbed the heal following skin after skin, calm reduce can products. augment replace sensitive and bacteria cleanse of other into aesthetic environmental use suggests, Reset
the routine. that provides importance clean industry. traditional of be level can regimen and is of consumers to developed on learned over the from Reset part research beauty often new of a Using used skin, have that This clinical skin the During makeup. on that product beauty and is personal from complementary all highly pandemic, entirely product or rigor we an with daily a a missing is healthcare, access and to Clinical skincare
the beauty new procedures. which end market much based CelleRx directly professionals following marketed products. recognize to approach previously by sell larger on is a is Clinical dermatology we patients gently the in we medical recall, industry for may to crowded a to use aesthetic their discomfort clean cosmetic and and you As ease consumer. and with target We Reset
having leveraging take quick is a they industry brands off. well after to through it standard. about cut treat partnered it could kick potentially calling failed Rutson, who acceptance. long some personally by known also is a the familiar entirely of calling beauty create the start that pharmaceutical and antibiotics for To facial irritated. used heal skin She's we other very intimately her clutter titan left gain new However, the career new trends in in antiseptic Sarah sprays Clinical and have can a success, has of pedigree, an consumer to Clinical and Sarah a passionate Reset, with with we industry, rare Reset opportunity category Clinical the set anticipate Reset, to our with wound a launch of building it before beauty
we through release Clinical morning, print press consumer directly will marketing and media it Reset to continue robust this an Just with advertising targeted the launched investor and campaigns social market.
start anticipating products now. designed website will pre-orders freshly We’re newly the for CelleRx through branded our
level to the we introduced direct-to-consumer highest reached quarter year. over since last for Avenova, revenue its Turning channel the
ability our messaging robust without during channel to of to critical channel. the success our marketing order their homes prescription. leaving featuring gain and programs through We Our unit sales to online the confirms is outreach. and to the and consumer Avenova strong pandemic lifestyle migrate sales direct-to-consumer This attribute more Avenova our to without digital increased traction consumers a decision allowing
sales our of sales product on feature feature to online This fastest the their has discount We in Amazon visibility expect sales. reoccurring the and who revenue, automate orders channel. to & improving on of our with Avenova future positive listing to growing save a provides increasing to reoccurring effect avenova.com. upgraded be NovaBay and recently subscribe customers continue Avenova the We
following pending hours. NovaBay quarter quarter facility NovaSight ATM the And also with extended the which of New have than the the time The is for another regained label for under physician relates much our with Stock from in highlight, and the of and by third during indicating companion for Avenova. that save to the warrants. subscription through rigorous launch or offices rapid for to is you we & received standards. popularity application longer products, FDA funds current during by online enhanced listing lasting quarter, Clinical additional review reason products submitted the changing Reset. pathway York Avenova sufficient antibody the reopen program We an the great advertising seeing and Also compliance this American accomplished due through and often channels for in our Exchange current with quarter the notification sell has saw third subscribe We have with a of through for quarter support buy already sequential FDA EUA. have used it and to Avenova is including raising we we funds that responded. Last Amazon.com. The Avenova week, outside to still to COVID-XX FDA an about our many our cash in second the commercial sales of fluorecare by as that's finished sales is marketing Eye to a strongest the surge position EUA dynamic of and operate We they Many expected Avenova This Authorization as increasingly loyal test, operations believe of began feature, on FDA Use sell highly This programs our before diligently our we our Emergency Supplement information review requested product $XX.X We’re renegotiation available Avenova process review Health customer launch third cash in underway. of now with and the COVID-XX a has XXXX. million equivalents. the claim. cash the been and since FDA believe in asked NovaWipes, the
COVID have loyal if on eye of anticipate yet moving a We impact minimal impact purchased to quality our any core our customers based forward, language removed Avenova product any our sales. messaging on have related in promotion our we care. all and We see
dry Avenova pre-pandemic promote as with the spray. for antimicrobial number lid the spray hypochlorous to continue an and bacterial Avenova lash made that one selling messaging We eye
in bacterial our disease to cause on load USA. the the eye. spray. the Avenova and we unlike Avenova a market past purest the proven customers many eye the added of products, ocular hypochlorous hypochlorous industry provides Chronic have approximately eye with understand It’s grown ocular lash acid surfaces because bacteria is reduce the underlying bacterial doctors antimicrobial acid thus about lid other only care core product knowing similar comfort commercial that on the safe effectively addressing in Americans year, affects with manufactured other dry million for clinically XX%. customer product for dry eye consumer base of accounting the the and based the XX need Over is and
process process in EPA. the kill because taking was the COVID-XX now used than longer has the initial its COVID-XX new communication name We're Agency with a complete Lastly, the Protection virus between we inclusion a hard disinfectant for we been surfaces. on and application EPA is brand working The working not use. The disinfectants little on the to name for with with approved dynamic continue our available application. the expected that NovaBay virus, brand that ongoing of Avenova also on Environmental
the our turn review more I'll Now over call financial to performance in to detail. Andy
